Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.53 |
| ▸ | MMP1 | P03956 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 6/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388106 | 0.91 | TSHR (0.53) | MMP13MMP1MMP9ADAM17GAA | |
| SCHEMBL7311624 | 0.88 | CYP2C9 (0.60) | MMP13MMP1MMP9ADAM17CYP2C9 | |
| SCHEMBL6818857 | 0.83 | ADAM17 (0.64) | MMP13MMP1MMP9ADAM17 | |
| SCHEMBL7324182 | 0.76 | MMP13 (0.53) | MMP13MMP1MMP9ADAM17CYP2C9 | |
| SCHEMBL5101263 | 0.75 | TSHR (0.68) | ADAM17GAASLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL7322996 | 0.75 | MMP9 (0.54) | MMP13MMP1MMP9ADAM17GAA | |
| SCHEMBL6645925 | 0.75 | POLB (0.48) | POLBALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4556005 | 0.75 | POLB (0.48) | POLBALDH1A1MAPTHTTKMT2A | |
| SCHEMBL7324037 | 0.73 | MMP9 (0.70) | MMP13MMP1MMP9ADAM17 | |
| SCHEMBL7317778 | 0.72 | MMP13 (0.66) | MMP13MMP1MMP9ADAM17CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470794-B2 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | MMP13 9/4885MMP1 1/4885MMP9 21/4885 |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | MMP1, MMP7, MMP2 | MMP13 9/4885MMP1 1/4885MMP9 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.